Breast Cancer News | Merck's Keytruda was approved in Europe for certain patients with TNBC

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

CMS News | US Healthcare News | Medicare and Medicaid News |

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

Gilead’s Trodelvy approved for triple-negative breast cancer in US

BMS’ and bluebird bio’s Abecma approved by US FDA; first CAR T cell therapy for multiple myeloma

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

Novartis’ blockbuster Entresto received the US FDA approval for a broader target population

US FDA approved BMS gene therapy Breyanzi

Merck and Bayer announced the US FDA approval for Verquvo

Expected best selling pharmaceutical products (drugs) in 2021

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

CMS News

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

To strengthen the oncology portfolio, Merck collaborated with Seattle Genetics, and Gilead acquired

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

FDA extended emergency use authorization of Veklury to all hospitalized patients

FDA has provided emergency use authorization for Abbott’s easy-to-use COVID-19 antigen test

FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment

Johnson and Johnson acquired Momenta Pharmaceuticals, aims to strength immunology profile

Amgen’s Kyprolis and Janssen’s Darzalex combination approved by the US FDA for multiple myeloma

Novartis Kesimpta approved for relapsing multiple sclerosis in the US

FDA says no to Gilead’s most anticipated product filgotinib

Genentech’s Enspryng approved for Neuromyelitis Optica Spectrum Disorder in the US

US FDA approved another drug for rare Duchenne Muscular Dystrophy

Gilead submitted NDA for Veklury to treat COVID-19 in the US

FDA approved Genentech’s Evrysdi for Spinal Muscular Atrophy

NOVARTIS COSENTYX APPROVED IN EUROPE FOR PAEDIATRIC PSORIASIS

GSK’s first anti-BCMA therapy Blenrep was approved in the US

Gilead’s CAR-T cell therapy approved for Relapsed or Refractory Mantle Cell Lymphoma

The US FDA approved Janssen’s psoriasis blockbuster for Psoriatic Arthritis

UNITED STATES HEALTHCARE SYSTEM

US FDA approved Rukobia (fostemsavir) for HIV patients who have limited treatment options

JANSSEN STOPPED PHASE 3 TRIAL OF ITS BLOCKBUSTER

US FDA approved Epizyme’s Tazverik for Relapsed/Refractory Follicular Lymphoma

Eli Lilly Lyumjev secures the US FDA approval for type-1 and type-2 diabetes

Novartis Ilaris to be the first FDA approved treatment for Adult-Onset Still’s Disease (AOSD)

FDA approved Novartis Cosentyx and Lilly’s Taltz for nr-axSpA in June

AMERICAN ACADEMY OF DERMATOLOGY CONFERENCE 2020

Viela Bio’s Uplizna received FDA approval for neuromyelitis optica spectrum disorder

Opdivo approved in the US for ESCC

Taltz was approved in the U.S. for non-radiographic axial spondyloarthritis

FDA approved Merck’s Recarbrio to treat hospital acquired pneumonia

Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients